Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Fineline Cube Feb 24, 2026
Company Deals

Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform

Fineline Cube Feb 14, 2026
Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Fineline Cube Feb 14, 2026
Company Deals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Fineline Cube Feb 14, 2026
Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Fineline Cube Feb 14, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

Fineline Cube Feb 24, 2026
Company Drug

Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China

Fineline Cube Feb 14, 2026
Company Drug

InnoCare Pharma’s Orelabrutinib Shows Efficacy in RRMS at ACTRIMS Forum

Fineline Cube Feb 27, 2025

Beijing-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the presentation of Phase II study results...

Company Drug

Jiangsu Hengrui’s HRS-1301 Receives NMPA Approval for Hyperlipidemia

Fineline Cube Feb 27, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its Category 1 chemical drug...

Company Drug

Hepalink Pharmaceutical’s Enoparin Receives Argentina Approval for Thromboembolic Diseases

Fineline Cube Feb 27, 2025

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that its subsidiary, Shenzhen Techdow...

Company Medical Device

Bio-heart’s Iberis System Approved by NMPA for Hypertension Treatment

Fineline Cube Feb 27, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced that its subsidiary, Shanghai Angiocare...

Company Drug

Fosun Pharma’s Tenapanor Approved in China for CKD Dialysis Patients

Fineline Cube Feb 27, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received...

Company Deals

WuXi XDC Expands MOU with LigaChem to Advance Next-Gen ADC Development

Fineline Cube Feb 26, 2025

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Deals

Kexing Biopharm and Bio-Sincerity Pharmaceutical Form Strategic Alliance

Fineline Cube Feb 26, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) and Hangzhou Bio-Sincerity Pharmaceutical Technology Co., Ltd. (SHE:...

Company Deals

Harbour BioMed Licenses HAT001/HBM9013 to Global Partner for CRH-Targeted Therapy

Fineline Cube Feb 26, 2025

China-based Harbour BioMed (HKG: 2142) announced a strategic collaboration and licensing agreement with an undisclosed...

Company Deals Hospital

Basecare and Rhea Labs Form Five-Year Alliance to Expand IVF Markets Globally

Fineline Cube Feb 26, 2025

China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has entered into a five-year...

Company Deals

Takeda Partners with BridGene to Develop Immunology and Neurology Drug Candidates

Fineline Cube Feb 26, 2025

Japan-based Takeda Pharmaceutical Company (NYSE: TAK, TYO: 4502) announced a partnership with US-based BridGene Biosciences,...

Company Deals

Hansoh Pharmaceutical’s HS-10561 Receives NMPA Clearance for Chronic Spontaneous Urticaria

Fineline Cube Feb 26, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received clinical trial...

Company Medical Device

J&J MedTech Launches Locally Produced HARMONIC 7s Scalpel in China

Fineline Cube Feb 26, 2025

Johnson & Johnson MedTech, a US-based healthcare giant, announced the official launch of its HARMONIC...

Company Deals

Thermo Fisher to Acquire Solventum’s Purification Business for USD 4.1B

Fineline Cube Feb 26, 2025

Thermo Fisher Scientific (NYSE: TMO) has agreed to acquire Solventum’s (NYSE: SOLV) Purification & Filtration...

Company Drug

J&J’s Tremfya Wins NMPA Approval for Crohn’s Disease Treatment

Fineline Cube Feb 26, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that its Tremfya (guselkumab) has received marketing approval...

Company Drug

Sanofi’s Sarclisa Wins New Japan Approval for Multiple Myeloma Combination Therapy

Fineline Cube Feb 26, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)...

Company Drug

YolTech Therapeutics’ YOLT-203 Shows Promise in Primary Hyperoxaluria Type 1 Trial

Fineline Cube Feb 26, 2025

YolTech Therapeutics, a Shanghai-based startup specializing in lipid nanoparticle delivery and gene editing, announced positive...

Company Deals

HQ Pharma and Shanghai Pharmaceuticals Expand Collaboration for Global Market Access

Fineline Cube Feb 26, 2025

China’s HQ Pharma (Shanghai) Co., Ltd has entered into a new collaboration agreement with Shanghai...

Company Deals

Green Valley and Vazyme Team Up on Alzheimer’s Disease Initiatives

Fineline Cube Feb 26, 2025

China-based Green Valley (Shanghai) Pharmaceuticals Co., Ltd. and Vazyme Biotech Co., Ltd (SHA: 688105) have...

Company Drug

Merck’s Keytruda sBLA for LA-HNSCC Accepted by FDA for Review

Fineline Cube Feb 26, 2025

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that the US Food and Drug...

Company Deals

CARsgen Therapeutics and Zhuhai SB Xinchuang Invest in UCARsgen for Allogeneic CAR-T Therapies

Fineline Cube Feb 26, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has entered into an agreement with an investment...

Posts pagination

1 … 165 166 167 … 625

Recent updates

  • Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China
  • Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit
  • FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies
  • Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel
  • Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights – $495M Deal Marks Metabolic Market Entry
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China

Company Drug

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Company Deals

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.